Payment overview · 2025
General Payments
$734.10
15 reported records · 9 companies
Healthcare provider profile · identity verified
Robert H Rivera, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BURBANK, CA · NPI 1659447977
Verified facts
What the public records show
CMS Open Payments records show Robert H Rivera, MD received $734.10 in general payments during 2025 across 15 reported records.
Novo Nordisk Inc accounted for 38.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $279.47 | 38.1% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $151.22 | 20.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $147.46 | 20.1% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $33.50 | 4.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $28.78 | 3.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.18 | 3.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.04 | 3.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.91 | 3.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.54 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $734.10 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $279.47 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $133.37 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $133.37 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $33.50 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.18 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 72 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
122 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
173 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 796 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 488 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 345 | 55 |
| Gabapentin | Gabapentin | 337 | 57 |
| Lisinopril | Lisinopril | 327 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 283 | 47 |
| Omeprazole | Omeprazole | 262 | 53 |
| Metformin Hcl | Metformin Hcl | 237 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 221 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 48 |
| Losartan Potassium | Losartan Potassium | 216 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 193 | 56 |
| Famotidine | Famotidine | 178 | 35 |
| Eliquis | Apixaban | 173 | 24 |
| Furosemide | Furosemide | 172 | 34 |
| Alendronate Sodium | Alendronate Sodium | 166 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 35 |
| Jardiance | Empagliflozin | 156 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 139 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 127 | 23 |
| Ozempic | Semaglutide | 127 | 22 |
| Tramadol Hcl | Tramadol Hcl | 127 | 30 |
| Linzess | Linaclotide | 122 | 29 |
| Benazepril Hcl | Benazepril Hcl | 118 | 24 |
| Finasteride | Finasteride | 116 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 112 | 20 |
| Lorazepam | Lorazepam | 108 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 14 |
| Mirtazapine | Mirtazapine | 100 | 21 |
| Januvia | Sitagliptin Phosphate | 93 | 19 |
| Irbesartan | Irbesartan | 92 | 21 |
| Trazodone Hcl | Trazodone Hcl | 86 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 82 | 16 |
| Glipizide | Glipizide | 81 | 24 |
| Levetiracetam | Levetiracetam | 80 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 14 |
| Donepezil Hcl | Donepezil Hcl | 78 | 16 |
| Kerendia | Finerenone | 77 | 16 |
| Farxiga | Dapagliflozin Propanediol | 72 | suppressed |
| Alprazolam | Alprazolam | 70 | 16 |
| Carvedilol | Carvedilol | 66 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 13 |
| Meclizine Hcl | Meclizine Hcl | 66 | 20 |
| Potassium Chloride | Potassium Chloride | 66 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 63 | 13 |
| Simvastatin | Simvastatin | 63 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 62 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 13 |
| Myrbetriq | Mirabegron | 62 | 16 |
| Cephalexin | Cephalexin | 61 | 34 |
| Ezetimibe | Ezetimibe | 61 | 13 |
| Clonazepam | Clonazepam | 60 | suppressed |
| Ibuprofen | Ibuprofen | 60 | 15 |
| Meloxicam | Meloxicam | 57 | 21 |
| Memantine Hcl Er | Memantine Hcl | 56 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 52 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 52 | suppressed |
| Glimepiride | Glimepiride | 51 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 51 | 16 |
| Naproxen | Naproxen | 50 | 12 |
| Allopurinol | Allopurinol | 48 | 13 |
| Pregabalin | Pregabalin | 48 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | suppressed |
| Latanoprost | Latanoprost | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 44 | 15 |
| Spironolactone | Spironolactone | 44 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 42 | 13 |
| Buspirone Hcl | Buspirone Hcl | 41 | suppressed |
| Vascepa | Icosapent Ethyl | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 39 | 16 |
| Prednisone | Prednisone | 39 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Temazepam | Temazepam | 37 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 16 |
| Lidocaine | Lidocaine | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Atenolol | Atenolol | 34 | 13 |
| Prolia | Denosumab | 34 | 26 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 27 |
| Hydrocortisone | Hydrocortisone | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Acyclovir | Acyclovir | 29 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Mupirocin | Mupirocin | 27 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Olanzapine Odt | Olanzapine | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 22 | suppressed |
| Demeclocycline Hcl | Demeclocycline Hcl | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Restasis | Cyclosporine | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lyrica | Pregabalin | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Tadalafil | Tadalafil | 18 | suppressed |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 11 |
| Olanzapine | Olanzapine | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Clozapine | Clozapine | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 14 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Orencia | Abatacept | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $734.10 · 15 records | Novo Nordisk Inc | AUSTEDO XR, FARXIGA, IBSRELA, NEXLETOL, NURTEC ODT, Ozempic, QULIPTA, Tymlos, UBRELVY, VRAYLAR, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error